| Dennis Wolf, | |
|
1 Gustave L Levy Pl, Anesthesiology - Box 1010, New York, NY 10029-6504 | |
| (800) 627-4470 | |
| (412) 937-5710 |
| Full Name | Dennis Wolf |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Location | 1 Gustave L Levy Pl, New York, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003981481 | NPI | - | NPPES |
| 015777715 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 161067 (New York) | Primary |
| Entity Name | Multi-specialty Pain Management Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891820726 PECOS PAC ID: 1254220650 Enrollment ID: O20040313000059 |
News Archive
Kaiser Permanente has announced its 2011 plans for individual Medicare-eligible beneficiaries, reflecting its commitment to continuing participation in Medicare in all its existing service areas in nine states and the District of Columbia.
PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, and the University of Massachusetts, have received a Phase I Small Business Technology Transfer (STTR) contract in the amount of $100,000 to support research to identify lead antimicrobial compounds to effectively treat multi-drug resistant and biofilm-embedded bacteria.
Actavis plc today announced that its subsidiary, Watson Laboratories, Inc., has filed suit against the U.S. Food and Drug Administration challenging the Agency's decision regarding its entitlement to shared 180-day marketing exclusivity for its generic version of Celebrex (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules.
During pregnancy, many women experience remission of autoimmune diseases like multiple sclerosis and uveitis. Now, scientists have described a biological mechanism responsible for changes in the immune system that helps to explain the remission.
GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma, presented final data from the G-202 Phase I clinical trial yesterday at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA.
› Verified 4 days ago
| Entity Name | Fpa Hospital Based |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629319413 PECOS PAC ID: 4789826694 Enrollment ID: O20130806000185 |
News Archive
Kaiser Permanente has announced its 2011 plans for individual Medicare-eligible beneficiaries, reflecting its commitment to continuing participation in Medicare in all its existing service areas in nine states and the District of Columbia.
PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, and the University of Massachusetts, have received a Phase I Small Business Technology Transfer (STTR) contract in the amount of $100,000 to support research to identify lead antimicrobial compounds to effectively treat multi-drug resistant and biofilm-embedded bacteria.
Actavis plc today announced that its subsidiary, Watson Laboratories, Inc., has filed suit against the U.S. Food and Drug Administration challenging the Agency's decision regarding its entitlement to shared 180-day marketing exclusivity for its generic version of Celebrex (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules.
During pregnancy, many women experience remission of autoimmune diseases like multiple sclerosis and uveitis. Now, scientists have described a biological mechanism responsible for changes in the immune system that helps to explain the remission.
GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma, presented final data from the G-202 Phase I clinical trial yesterday at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dennis Wolf, Po Box 5024, New York, NY 10087-5024 Ph: (800) 627-4470 | Dennis Wolf, 1 Gustave L Levy Pl, Anesthesiology - Box 1010, New York, NY 10029-6504 Ph: (800) 627-4470 |
News Archive
Kaiser Permanente has announced its 2011 plans for individual Medicare-eligible beneficiaries, reflecting its commitment to continuing participation in Medicare in all its existing service areas in nine states and the District of Columbia.
PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, and the University of Massachusetts, have received a Phase I Small Business Technology Transfer (STTR) contract in the amount of $100,000 to support research to identify lead antimicrobial compounds to effectively treat multi-drug resistant and biofilm-embedded bacteria.
Actavis plc today announced that its subsidiary, Watson Laboratories, Inc., has filed suit against the U.S. Food and Drug Administration challenging the Agency's decision regarding its entitlement to shared 180-day marketing exclusivity for its generic version of Celebrex (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules.
During pregnancy, many women experience remission of autoimmune diseases like multiple sclerosis and uveitis. Now, scientists have described a biological mechanism responsible for changes in the immune system that helps to explain the remission.
GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma, presented final data from the G-202 Phase I clinical trial yesterday at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA.
› Verified 4 days ago
Dr. Jason H Epstein, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 423 E 23rd St, New York, NY 10010 Phone: 212-686-7500 | |
Dr. Aisha Baqai, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 525 E 68th St # M-312, New York, NY 10065 Phone: 212-746-2941 Fax: 212-746-8713 | |
Dr. Donna Bracken, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 506 Malcolm X Blvd, New York, NY 10037 Phone: 212-939-1000 | |
Michael Newman Singleton, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 535 E 70th St, New York, NY 10021 Phone: 212-606-1036 | |
Dr. Thor Lidasan, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 462 1st Ave # A-560, New York, NY 10016 Phone: 212-562-2300 Fax: 212-562-3486 | |
Kenneth H Jacobson, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 550 1st Ave, New York, NY 10016 Phone: 212-263-5072 | |
Roni Mendonca, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: Metropolitan Hospital, 1901 1st Ave 5 South 2, New York, NY 10029 Phone: 212-423-7095 |